

26 November 2010

The Manager  
 Company Announcements Office  
 ASX Limited  
 20 Bridge St  
 SYDNEY, NSW, 2000

Dear Sir,

### RESULTS OF GENERAL MEETING

We wish to advise that resolutions put to the Annual General Meeting of CBio Limited held today were each passed on a show of hands.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution as follows:-

	<b>Total number of votes</b>	<b>For the resolution</b>	<b>At proxy's discretion</b>	<b>Against resolution</b>	<b>Abstain from resolution</b>
<b>Resolution 1</b>					
Remuneration Report	32,513,297	25,882,595	750,084	5,428,848	451,770
<b>Resolution 2</b>					
Election of Dr Göran Ando	32,513,297	29,601,051	750,084	2,112,003	50,159
<b>Resolution 3</b>					
Election of Professor John Funder, AO	32,513,297	29,611,051	750,084	2,112,003	40,159
<b>Resolution 4</b>					
Ratification of previous allotment and issue of securities	32,513,297	23,421,575	833,371	5,188,442	3,069,909

For and on behalf of the Board

**BEN GRAHAM**  
 Company Secretary

For further information:

Ben Graham  
Company Secretary  
CBio Limited  
T: +61 7 3841 4844  
[ben.graham@cbio.com.au](mailto:ben.graham@cbio.com.au)

**About CBio:**

CBio is an Australian ASX listed company established in 2000. CBio's lead product XToll is a potential new-generation drug therapy which could provide safer and more effective treatment of autoimmune diseases such as rheumatoid arthritis. It is currently being trialled in phase II clinical trials in patients with rheumatoid arthritis (RA). Global sales of RA therapies exceeded US\$17 billion in 2008.

Novo Nordisk A/S, a top 20 global pharmaceutical company and world-leader in diabetes care, has an exclusive option to enter into a licence agreement for the intellectual property rights relating to XToll.

CBio's Board includes internationally experienced drug developers including Dr Goran Ando, Vice-Chairman Novo Nordisk A/S (formerly president of R&D at Pharmacia/Pfizer and R&D director of Glaxo Group, UK); Dr Peter Corr, Founder and co-General Partner of Celtic Therapeutics (formerly Senior Vice-President for Science and Technology at Pfizer and Chairman of the Board of Governors, New York Academy of Sciences); and Professor John Funder, AO, Professor of Medicine at Monash University, Senior Fellow at Prince Henry's Institute of Medical Research (formerly Director of the Baker Institute, 1990-2001).